Bupivacaine

Generic Name: Bupivacaine

Brand Names: Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₈N_₂O

CAS Number: 38396-39-3

Unique Ingredient Identifier: Y8335394RO

Background: Bupivacaine is a widely used local anesthetic agent.

Indication: As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions

Associated Therapies: General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy

Clinical Trials

A Comparison of Epidural Techniques for Labour Analgesia

Not Applicable

Completed

Conditions: Labour Analgesia

Interventions: Drug: Bupivacaine

First Posted Date: 2017-02-28

Last Posted Date: 2018-05-24

Lead Sponsor: University of British Columbia

Target Recruit Count: 150

Registration Number: NCT03065569

Locations: 🇨🇦
British Columbia's Women's Hospital, Vancouver, British Columbia, Canada
🇨🇦
BC Women's Hospital, Vancouver, British Columbia, Canada

Status Migrainosus - Differentiating Between Responders and Non-responders

Phase 1

Conditions: Migraine

Interventions: Drug: Naratriptan Pill
Drug: Bupivacaine
Drug: Dexamethasone
Drug: Ketorolac

First Posted Date: 2017-02-28

Last Posted Date: 2018-08-31

Lead Sponsor: Hartford HealthCare

Target Recruit Count: 50

Registration Number: NCT03066544

Locations: 🇺🇸
Hartford HealthCare Headache Center, Wethersfield, Connecticut, United States

Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block

Phase 3

Conditions: Breast Cancer Female

Interventions: Drug: Dexmedetomidine Injection [Precedex]
Drug: Bupivacaine

First Posted Date: 2017-02-24

Last Posted Date: 2017-02-24

Lead Sponsor: South Egypt Cancer Institute

Target Recruit Count: 60

Registration Number: NCT03063073

Locations: 🇪🇬
South EGYPT cancer institute, Assuit, Egypt

PECS Block: Plasma Bupivacaine Level

Early Phase 1

Completed

Conditions: Nerve Blocks

Interventions: Procedure: Unilateral PECS I and II block
Procedure: Bilateral PECS I and II block
Drug: Bupivacaine

First Posted Date: 2017-02-23

Last Posted Date: 2021-10-15

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 20

Registration Number: NCT03059498

Locations: 🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Efficacy of Liposomal Bupivacaine for Pain Control After Percutaneous Nephrostolithotomy

Phase 3

Withdrawn

Conditions: Renal Calculi
Postoperative Pain

Interventions: Drug: Saline Solution
Drug: liposomal bupivicaine
Drug: Bupivacaine

First Posted Date: 2017-02-03

Last Posted Date: 2017-08-28

Lead Sponsor: Northwell Health

Registration Number: NCT03043027

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

Phase 1

Completed

Conditions: Surgery
Pelvic Organ Prolapse
Postoperative Pain

Interventions: Drug: Bupivacaine
Drug: Dexamethasone
Procedure: Bilateral Levator Ani Muscle Injection
Procedure: Bilateral Pudendal Nerve Block
Drug: Saline